Skip to search form
Skip to main content
Skip to account menu
Semantic Scholar
Semantic Scholar's Logo
Search 210,177,770 papers from all fields of science
Search
Sign In
Create Free Account
avagacestat
Known as:
(2R)-2-(N-((4-Chlorophenyl)sulfonyl)-N-((2-fluoro-4-(1,2,4-oxadiazol-3-yl)phenyl)methyl)amino)-5,5,5-trifluoropentanamide
, Pentanamide, 2-(((4-chlorophenyl)sulfonyl)((2-fluoro-4-(1,2,4-oxadiazol-3-yl)phenyl)methyl)amino)-5,5,5-trifluoro-, (2R)-
National Institutes of Health
Create Alert
Alert
Related topics
Related topics
1 relation
Broader (1)
BMS 708163
Papers overview
Semantic Scholar uses AI to extract papers important to this topic.
2018
2018
Nonclinical Safety Assessment of the &ggr;-Secretase Inhibitor Avagacestat
F. Simutis
,
T. Sanderson
,
G. Pilcher
,
M. Graziano
Toxicological Sciences
2018
Corpus ID: 3846822
The toxicity of avagacestat, a sulfonamide-based gamma (γ)-secretase inhibitor that was in development as a treatment for…
Expand
Highly Cited
2015
Highly Cited
2015
Targeting Prodromal Alzheimer Disease With Avagacestat: A Randomized Clinical Trial.
V. Coric
,
S. Salloway
,
+25 authors
R. Berman
JAMA Neurology
2015
Corpus ID: 4402658
IMPORTANCE Early identification of Alzheimer disease (AD) is important for clinical management and affords the opportunity to…
Expand
Highly Cited
2015
Highly Cited
2015
The interplay of the Notch signaling in hepatic stellate cells and macrophages determines the fate of liver fibrogenesis
Ruchi Bansal
,
J. van Baarlen
,
G. Storm
,
J. Prakash
Scientific Reports
2015
Corpus ID: 3232413
Hepatic stellate cells (HSCs) known as “master producers” and macrophages as “master regulators”, are the key cell types that…
Expand
Review
2014
Review
2014
Potential novel targets for Alzheimer pharmacotherapy: II. Update on secretase inhibitors and related approaches
J. A. Mikulca
,
V. Nguyen
,
+6 authors
R. Raffa
Journal of Clinical Pharmacy and Therapeutics
2014
Corpus ID: 22153091
The prevailing theory regarding Alzheimer disease (AD) is that insoluble amyloid β‐peptide (Aβ) plays a critical role in the…
Expand
Highly Cited
2013
Highly Cited
2013
Pharmacodynamics of Selective Inhibition of γ-Secretase by Avagacestat
C. Albright
,
R. Dockens
,
+30 authors
G. Tong
Journal of Pharmacology and Experimental…
2013
Corpus ID: 15656980
A hallmark of Alzheimer’s disease (AD) pathology is the accumulation of brain amyloid β-peptide (Aβ), generated by γ-secretase…
Expand
2013
2013
A contrast in safety, pharmacokinetics and pharmacodynamics across age groups after a single 50 mg oral dose of the γ-secretase inhibitor avagacestat.
G. Tong
,
Jun-sheng Wang
,
+11 authors
R. Dockens
British Journal of Clinical Pharmacology
2013
Corpus ID: 31772750
AIM To evaluate the single dose pharmacokinetics, pharmacodynamics, and preliminary tolerability of the γ-secretase inhibitor BMS…
Expand
Highly Cited
2012
Highly Cited
2012
Safety and tolerability of the γ-secretase inhibitor avagacestat in a phase 2 study of mild to moderate Alzheimer disease.
V. Coric
,
C. V. van Dyck
,
+18 authors
R. Berman
Archives of Neurology
2012
Corpus ID: 17855205
OBJECTIVE To assess the safety, tolerability, and pharmacokinetic and pharmacodynamic effects of the -secretase inhibitor…
Expand
2012
2012
A Placebo-Controlled, Multiple Ascending Dose Study to Evaluate the Safety, Pharmacokinetics and Pharmacodynamics of Avagacestat (BMS-708163) in Healthy Young and Elderly Subjects
R. Dockens
,
Jun-sheng Wang
,
+10 authors
G. Tong
Clinical Pharmacokinetics
2012
Corpus ID: 7019077
Background and ObjectivesAvagacestat is an orally active γ-secretase inhibitor that selectively inhibits amyloid β (Aβ) synthesis…
Expand
Highly Cited
2012
Highly Cited
2012
BMS-708,163 targets presenilin and lacks notch-sparing activity.
Christina J. Crump
,
Suita V Castro
,
+6 authors
Yue-Ming Li
Biochemistry
2012
Corpus ID: 206844918
The "Notch-sparing" γ-secretase inhibitor (GSI) BMS-708,163 (Avagacestat) is currently in phase II clinical trials for Alzheimer…
Expand
2012
2012
Effects of Single Doses of Avagacestat (BMS-708163) on Cerebrospinal Fluid Aβ Levels in Healthy Young Men
G. Tong
,
Lorna Castaneda
,
+10 authors
R. Dockens
Clinical drug investigation
2012
Corpus ID: 30640997
BackgroundThe concentration of amyloid β (Aβ) peptides in cerebrospinal fluid (CSF) is a biomarker for Alzheimer’s disease (AD…
Expand
By clicking accept or continuing to use the site, you agree to the terms outlined in our
Privacy Policy
(opens in a new tab)
,
Terms of Service
(opens in a new tab)
, and
Dataset License
(opens in a new tab)
ACCEPT & CONTINUE